Open Access Articles- Top Results for Jimscaline


Systematic (IUPAC) name
Clinical data
  • Uncontrolled
890309-57-6 7pxN
PubChem CID 11673493
ChemSpider 9848222 7pxN
Chemical data
Formula C13H19NO3
237.294 g/mol
 14pxN (what is this?)  (verify)

Jimscaline (C-(4,5,6-trimethoxyindan-1-yl)methanamine) is a conformationally-restricted derivative of the cactus-derived hallucinogen mescaline, which was discovered in 2006 by a team at Purdue University led by David E. Nichols. It acts as a potent agonist for the 5-HT2A and 5-HT2C receptors with the more active (R)-enantiomer having a Ki of 69 nM at the human 5-HT2A receptor, and around three times the potency of mescaline in drug-substitution experiments in animals.[1] This discovery that the side chain of the phenethylamine hallucinogens could be constrained to give chiral ligands with increased activity then led to the later development of the super-potent benzocyclobutene derivative TCB-2.[2][3]

See also


  1. ^ McLean TH, Chambers JJ, Parrish JC, Braden MR, Marona-Lewicka D, Kurrasch-Orbaugh D, Nichols DE (13 July 2006), "C-(4,5,6-trimethoxyindan-1-yl)methanamine: a mescaline analogue designed using a homology model of the 5-HT2A receptor.", Journal of Medicinal Chemistry 49 (14): 4269–74, PMID 16821786, doi:10.1021/jm060272y 
  2. ^ McLean TH, Parrish JC, Braden MR, Marona-Lewicka D, Gallardo-Godoy A, Nichols DE (21 September 2006), "1-Aminomethylbenzocycloalkanes: conformationally restricted hallucinogenic phenethylamine analogues as functionally selective 5-HT2A receptor agonists.", Journal of Medicinal Chemistry 49 (19): 5794–803, PMID 16970404, doi:10.1021/jm060656o 
  3. ^ Michael Robert Braden PhD. Towards a biophysical understanding of hallucinogen action. Purdue University 2007.

Lua error in package.lua at line 80: module 'Module:Buffer' not found.